Pemazyre (Pemigatinib).
- Medicine Name: Pemazyre
- Generic Name: Pemigatinib
- Dosage Form & Strength: Tablets: 4.5mg, 9mg & 13.5mg
- Manufactured By: Incyte Corporation
Pemazyre is a kinase inhibitor used for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.
Recommended Dosage: The recommended dosage is 13.5 mg orally once a day for 2 consecutive weeks followed by 1 week off therapy, in 3 week cycles. Continue treatment until the disease is progressive or unacceptable toxicity occurs.
Take pemazyre tablets with or without food at around the same time every day. Swallow tablets completely. Do not chew, crush, split, or dissolve tablets. In case the patient misses any dose by 4 or more hours or in case vomiting occurs, dosing should be resumed with the upcoming scheduled dose.
- Tablets of pemazyre can cause RPED, which may cause signs/symptoms such as blurred vision, visual floaters, or photopsia. Comprehensive ophthalmological examination needs to be done including OCT before initiating pemazyre 9 mg / 4.5 mg / 13.5 mg tablet therapy and every 2 months for the initial 6 months and every 3 months thereafter while on treatment.
- Monitor patients for hyperphosphatemia and start a low phosphate diet when the level of serum phosphate is > 5.5 mg/dL. For the serum phosphate levels > 7 mg/dL, start phosphate lowering therapy and withhold, reduce the dose, or permanently interrupt pemazyre tablet 4.5mg / 9mg / 13.5mg based on time-span and severity of hyperphosphatemia.
- Findings in animal study and its mechanism of action suggest that pemazyre may cause fetal harm in cases administered to pregnant females. Advise females reproductive age to use effective contraception while on treatment with pemazyre tablet 13.5mg / 9mg / 4.5mg and for 1 week after the final dose.
- Valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients Identity Proof (issued by government of India)
- Valid prescription of Doctor
- Import permit if applicable
- On availability in India (Delhi, Mumbai, Kolkata, Hyderabad, Ahmedabad, Chennai, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
- Indian Pharma Network is able to source the PEMAZYRE (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
- Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
What is the Generic Name for the trade name drug Pemazyre®?
Pemigatinib is Generic Name for the trade name drug Pemazyre®.
What is the Manufacturer Name of Pemazyre®?
Pemazyre® is manufactured by Incyte Corporation.
Is Pemazyre® approved by the FDA?
Yes, Pemazyre® is approved by the FDA. Date of approval: April 17, 2020.
What is Pemazyre®?
Pemazyre® is the first FDA-approved prescription agent that is aimed to treat adult patients with bile duct cancer (cholangiocarcinoma) that has spread or difficult to be removed by surgery:
- who have already treated with previous therapy, and
- whose tumor has a certain kind of abnormal “FGFR2” gene
What is the dosage and form of Pemazyre® supplied?
Pemazyre® is supplied as Tablets: 4.5mg, 9mg & 13.5mg for oral administration.
What are the most common side effects due to Pemazyre®?
Most common side effects due to Pemazyre® include: nail toxicity, hyperphosphatemia, alopecia, diarrhea, fatigue, dysgeusia, constipation, nausea, stomatitis, dry eye, dry mouth, vomiting, arthralgia, decreased appetite, back pain, abdominal pain, hypophosphatemia, and dry skin.
How much does Pemigatinib cost in India?
The pemigatinib cost in India is less and reasonable. In order to procure this cholangiocarcinoma medication authentically, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Pemazyre®?
Store the tablets of Pemazyre at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).
What are the Highlights of prescribing information for Pemazyre®?
Click Here to download full Pemazyyre prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.